About TikkunLev Therapuetics

We were founded to leverage the groundbreaking research of our Co-Founder and Chief Scientific Officer, Professor Robin Shaw M.D., Ph.D., and his team at the Nora Eccles Harrison Cardiovascular Research and Training Institute at the University of Utah

#1

cause of death globally

Cardiovascular disease remains the number 1 cause of death globally

1 out of 4

individuals

1 out of 4 individuals will develop heart failure in their lifetime

Counter

1 person

every minute

1 person is diagnosed with heart failure every 60 seconds in the United States

TikkunLev

ti•kkun•lev

Hebrew for “Repairing the Heart”

Our vision is to transform the treatment of heart failure by targeting the underlying biology of failing heart muscle

Our Lead Program

TLT-101 is a precision therapy designed to target the underlying biology of failing heart muscle

Heart Image

Comprehensive preclinical studies demonstrate an unprecedented efficacy and safety profile with a one-time low IV dose

We have the unique ability to leverage a blood-based biomarker to enable a precision therapy paradigm